Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Дек. 8, 2023
Developing
effective
vaccines
against
viral
infections
have
significant
impacts
on
development,
prosperity
and
well-being
of
human
populations.
Thus,
successful
such
as
smallpox
polio
vaccines,
promoted
global
societal
well-being.
In
contrast,
ineffective
may
fuel
arguments
that
retard
scientific
progress.
We
aim
to
stimulate
a
multilevel
discussion
how
develop
recent
future
pandemics
by
focusing
acquired
immunodeficiency
syndrome
(AIDS),
coronavirus
disease
(COVID)
other
infections.
appeal
harnessing
achievements
in
this
field
specifically
towards
cure
for
current
prevention
the
next
pandemics.
Among
these,
we
propose
apply
HIV
DNA
chromatin
format
–
an
end
product
aborted
integration
episomal
forms,
i.e.,
(cVacc),
elicit
epigenetic
silencing
memory
prevent
replication
infection.
Nature,
Год журнала:
2023,
Номер
626(7998), С. 385 - 391
Опубликована: Дек. 14, 2023
Abstract
A
limitation
of
current
SARS-CoV-2
vaccines
is
that
they
provide
minimal
protection
against
infection
with
Omicron
subvariants
1,2
,
although
still
severe
disease.
Enhanced
mucosal
immunity
may
be
required
to
block
and
onward
transmission.
Intranasal
administration
has
proven
inconsistent
3–7
suggesting
alternative
immunization
strategies
required.
Here
we
show
intratracheal
boosting
a
bivalent
Ad26-based
vaccine
results
in
substantial
induction
humoral
cellular
near-complete
BQ.1.1
challenge.
total
40
previously
immunized
rhesus
macaques
were
boosted
Ad26
by
the
intramuscular,
intranasal
routes,
or
mRNA
route.
route
led
expansion
neutralizing
antibodies,
IgG
IgA
binding
CD8
+
CD4
T
cell
responses,
which
exceeded
those
induced
intramuscular
routes.
Intratracheal
also
robust
upregulation
cytokine,
natural
killer,
B
pathways
lungs.
After
challenge
high
dose
BQ.1.1,
provided
protection,
whereas
other
proved
less
effective.
Protective
efficacy
correlated
best
immune
responses.
These
data
demonstrate
these
induce
immunity,
feasibility
developing
respiratory
viral
infections.
Technology Analysis and Strategic Management,
Год журнала:
2024,
Номер
unknown, С. 1 - 15
Опубликована: Июль 30, 2024
The
risk
of
failure
in
innovation
projects
affects
organisational
behaviour
and
the
performance
firms.
This
study
develops
a
theory
errors
project-level
failure.
Error
is
set
faults
that
generates
deviations
phases
R&D
process
projects,
decreasing
expected
results.
From
systemic
perspective,
project
due
to
negative
outcome.
proposed
clarifies
general
determinants
are
design,
execution
market
orientation.
Case
studies
drug
discovery
industry
pharmaceuticals
validate
consistency
theory,
giving
examples
leading
failures.
payoff
matrix
success/failure
occurrences
predicts
probability
can
double
by
setting
difficult
goal
compared
an
easy
one.
Inductive
implications
organisations
reduce
with
better
adaptedness
changes
minimise
learn
from
them.
guide
managers,
designers,
etc.
detecting
critical
apply
strategies
problem
solving
based
on
winning
approach
learning
lead
enable
organisation
adapt,
take
advantage
important
opportunities
cope
consequential
environmental
threats
for
achieving
goals
sustaining
competitive
turbulent
markets.
Emerging Microbes & Infections,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 20, 2025
The
unanticipated
emergence
of
the
COVID-19
pandemic
and
rapid
spread
mpox
epidemic
in
2022
2024
brought
unforeseen
challenges
to
public
health.
While
distinct
nature,
these
outbreaks
share
some
similarities
offer
valuable
insights
into
responding
novel
virus
dissemination
vulnerable
populations.
In
light
two
experiences,
we
aim
discern
prioritization
medical
countermeasures
(MCM)
among
antivirals,
antibodies
vaccines.
Vaccines,
Год журнала:
2025,
Номер
13(4), С. 424 - 424
Опубликована: Апрель 17, 2025
Vaccination
has
been
instrumental
in
curbing
the
transmission
of
SARS-CoV-2
and
mitigating
severity
clinical
manifestations
associated
with
COVID-19.
Numerous
COVID-19
vaccines
have
developed
to
this
effect,
including
BioNTech-Pfizer
Moderna’s
mRNA
vaccines,
as
well
adenovirus
vector-based
such
Oxford–AstraZeneca.
However,
emergence
new
variants
subvariants
SARS-CoV-2,
characterized
by
enhanced
transmissibility
immune
evasion,
poses
significant
challenges
efficacy
current
vaccination
strategies.
In
review,
we
aim
comprehensively
outline
landscape
emerging
concern
(VOCs)
sub-lineages
that
recently
surfaced
post-pandemic
years.
We
assess
effectiveness
existing
their
booster
doses,
against
these
subvariants,
BA.2-derived
sub-lineages,
XBB
BA.2.86
(Pirola).
Furthermore,
discuss
latest
advancements
vaccine
technology,
multivalent
pan-coronavirus
approaches,
along
development
several
next-generation
coronavirus
exosome-based,
virus-like
particle
(VLP),
mucosal,
nanomaterial-based
vaccines.
Finally,
highlight
key
critical
areas
for
future
research
address
evolving
threat
develop
strategies
combating
viral
threats,
thereby
improving
preparedness
pandemics.
Nature Communications,
Год журнала:
2023,
Номер
14(1)
Опубликована: Окт. 24, 2023
A
pan-sarbecovirus
or
pan-betacoronavirus
vaccine
that
can
prevent
current
and
potential
future
beta-coronavirus
infections
is
important
for
fighting
possible
pandemics.
Here,
we
report
a
mucosal
cross-protects
small
animal
models
from
sarbecoviruses
including
SARS-CoV-1,
SARS-CoV-2
its
variants.
The
comprises
live-but-defective
virus
envelope
deficient
has
the
orf8
segment
replaced
by
interferon-beta,
hence
named
Interferon
Beta
Integrated
(IBIS)
vaccine.
Nasal
vaccination
with
IBIS
protected
mice
lethal
homotypic
infection
hamsters
co-housing-mediated
transmission
of
virus.
Moreover,
provided
complete
protection
against
heterotypic
sarbecoviruses,
Delta
Omicron
variants,
SARS-CoV-1
in
both
hamsters.
Besides
inducing
strong
lung
CD8
+
T
cell
response,
specifically
heightened
activation
virus-specific
CD4
cells
compared
to
interferon-null
direct
production
interferon
also
suppressed
co-infection
human
cells,
reducing
risk
genetic
recombination
when
using
as
live
vaccines.
Altogether,
next-generation
warrants
further
clinical
investigations.
Abstract
Coronaviruses
(CoVs)
have
caused
three
global
outbreaks:
severe
acute
respiratory
syndrome
coronavirus
1
(SARS-CoV-1)
in
2003,
Middle
East
(MERS-CoV)
2012,
and
SARS-CoV-2
2019,
with
significant
mortality
morbidity.
The
impact
of
disease
2019
(COVID-19)
raised
serious
concerns
about
the
preparedness
for
a
pandemic.
Furthermore,
changing
antigenic
landscape
led
to
new
variants
increased
transmissibility
immune
evasion.
Thus,
development
broad-spectrum
vaccines
against
current
future
emerging
CoVs
will
be
an
essential
tool
pandemic
preparedness.
Distinct
phylogenetic
features
within
complicate
limit
process
generating
pan-CoV
vaccine
capable
targeting
entire
Coronaviridae
family.
In
this
review,
we
aim
provide
detailed
overview
CoVs,
their
phylogeny,
various
efforts
developing
vaccines,
future.
EClinicalMedicine,
Год журнала:
2023,
Номер
67, С. 102374 - 102374
Опубликована: Дек. 13, 2023
The
pivotal
phase
3
efficacy
clinical
trial
has
demonstrated
that
a
two-dose
regimen
of
dNS1-RBD
(Beijing
Wantai
Biological
Pharmacy
Enterprise,
Beijing,
China)
is
well-tolerated
and
provides
wide
protection
against
SARS-CoV-2
infection.
However,
the
effectiveness
single-dose
still
unknown.
We
aimed
to
estimate
one-dose
symptomatic
Omicron
infections
in
real-world
conditions.
